Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2345094 | 1.00 | ACE (0.45) | ACEMEN1KMT2AMMP2MMP9 | |
| SCHEMBL28959657 | 0.98 | ACE (0.44) | ACEMEN1KMT2AMMP2MMP9 | |
| SCHEMBL29929647 | 0.78 | ACE (0.33) | ACEMMP2MMP9 | |
| SCHEMBL28228231 | 0.77 | ACE (0.45) | ACEMEN1KMT2AMMP2MMP9 | |
| SCHEMBL23211224 | 0.76 | ACE (0.44) | ACEMEN1KMT2AMMP2MMP9 | |
| SCHEMBL18832362 | 0.76 | ACE (0.44) | ACEMEN1KMT2AMMP2MMP9 | |
| SCHEMBL2715722 | 0.76 | ACE (0.56) | ACEMEN1KMT2AMMP2MMP9 | |
| SCHEMBL11707855 | 0.76 | ACE (0.44) | ACEMEN1KMT2AMMP2MMP9 | |
| SCHEMBL9630278 | 0.76 | ACE (0.44) | ACEMEN1KMT2AMMP2MMP9 | |
| SCHEMBL2805870 | 0.76 | ACE (0.56) | ACEMEN1KMT2AMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1582514-B1 | PROCESSES FOR PRODUCING GLUTAMIC ACID DERIVATIVE, A PYROGLUTAMIC ACID DERIVATIVE AND A NOVEL INTERMEDIATE FOR PRODUCTION | AJINOMOTO KK (JP) | 2011-08-31 | — | — | EP | claimed |
| US-7674915-B2 | Process for manufacturing a glutamic acid derivative and a pyroglutamic acid derivative and a novel intermediate in the manufacture thereof | AJINOMOTO CO., INC. (JP) | 2010-03-09 | — | — | US | claimed |
| US-20060009394-A1 | Process for manufacturing a glutamic acid derivative and a pyroglutamic acid derivative and a novel intermediate in the manufacture thereof | AJINOMOTO CO. INC (JP) | 2006-01-12 | — | — | US | claimed |
| EP-1582514-A1 | PROCESSES FOR PRODUCING GLUTAMIC ACID DERIVATIVE AND PYROGLUTAMIC ACID DERIVATIVE AND NOVEL INTERMEDIATE FOR PRODUCTION | Ajinomoto Co., Inc. (JP) | 2005-10-05 | — | — | EP | claimed |
| US-8394970-B2 | Process for manufacturing a glutamic acid derivative and a pyroglutamic acid derivative and a novel intermediate in the manufacture thereof | AJINOMOTO CO., INC. (JP) | 2013-03-12 | — | — | US | disclosed |
| EP-1582514-B1 | PROCESSES FOR PRODUCING GLUTAMIC ACID DERIVATIVE, A PYROGLUTAMIC ACID DERIVATIVE AND A NOVEL INTERMEDIATE FOR PRODUCTION | AJINOMOTO KK (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-7674915-B2 | Process for manufacturing a glutamic acid derivative and a pyroglutamic acid derivative and a novel intermediate in the manufacture thereof | AJINOMOTO CO., INC. (JP) | 2010-03-09 | — | — | US | disclosed |
| US-20100010234-A1 | PROCESS FOR MANUFACTURING A GLUTAMIC ACID DERIVATIVE AND A PYROGLUTAMIC ACID DERIVATIVE AND A NOVEL INTERMEDIATE IN THE MANUFACTURE THEREOF | AJINOMOTO CO. INC (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20060009394-A1 | Process for manufacturing a glutamic acid derivative and a pyroglutamic acid derivative and a novel intermediate in the manufacture thereof | AJINOMOTO CO. INC (JP) | 2006-01-12 | — | — | US | disclosed |
| EP-1582514-A1 | PROCESSES FOR PRODUCING GLUTAMIC ACID DERIVATIVE AND PYROGLUTAMIC ACID DERIVATIVE AND NOVEL INTERMEDIATE FOR PRODUCTION | Ajinomoto Co., Inc. (JP) | 2005-10-05 | — | — | EP | disclosed |
| WO-2001054500-A1 | USE OF PROLINES FOR IMPROVING GROWTH AND OTHER PROPERTIES OF PLANTS AND ALGAE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010234-A1 | PROCESS FOR MANUFACTURING A GLUTAMIC ACID DERIVATIVE AND A PYROGLUTAMIC ACID DERIVATIVE AND A NOVEL INTERMEDIATE IN THE MANUFACTURE THEREOF | PTMA, GRIK5, GLUL | ACE 4125/4885MEN1 195/4885KMT2A 116/4885 |
| US-20060009394-A1 | Process for manufacturing a glutamic acid derivative and a pyroglutamic acid derivative and a novel intermediate in the manufacture thereof | PTMA, GRIK5, GLUL | ACE 4125/4885MEN1 195/4885KMT2A 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.